Hereditary transthyretin amyloidosis (HTA) Program in Pharmaceutical Benefits Scheme (PBS) 012-24070419

This document outlines details of PBS-subsidised patisiran for patients with hereditary transthyretin amyloidosis (HTA).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Hereditary transthyretin amyloidosis (HTA) quick reference

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial PB367 form	Written Electronic S100: patisiran	No	OPA	Must be treated by or in consultation with a: consultant with experience in the management of amyloid disorders	Yes
Grandfather PB369 form	Written Electronic S100: patisiran	No	OPA	Not specified	Yes
Continuing PB368 form	Written Electronic S100: patisiran	No	OPA	Not specified	Yes